Cefaly, created by New York-based Cefaly Technology, is an electronic, battery-powered device that is placed on the forehead for 20 minutes a day. Cefaly sends small electrical impulses through the skin to desensitizes the trigeminal nerve and reduce the frequency of migraines.
The company just released a new version of the device that is three-quarters the size of the original, fits in the palm of one’s hand, is rechargeable and allows patients to control the intensity of the electrical pulses.
In a recent clinical trial of the updated device — called Cefaly 2 — 81 percent of patients reported a significant reduction in migraine attacks, while 75 percent showed a reduction in the use of migraine medications.
Cefaly 2 is currently available by prescription in the U.S. and costs $349.
More articles on medical devices:
FDA approves Abbott’s intraocular lenses to treat cataracts
FDA lauds potential of 3D printing for personalized medicine
How the pause in medical device taxes helps medtechs grow
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
